Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
JUBLPHARMA
Mr. Priyavrat Bhartia MBA · Noida, India
₹961.65
▼-1.61%Jubilant Pharma has been steadily improving, but remains a high-debt player in a competitive sector with moderate growth prospects.
Exchange
NSI
Currency
INR
Day range
₹956.25 – ₹979.95
52-week range
₹786.05 – ₹1,233.10
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis60% confidence
While Jubilant Pharma trades around its 1-year high, suggesting a relatively optimistic market view, the high debt levels and competitive sector dynamics temper its valuation, suggesting a fair-value range of 850-950 INR.
22.0% below the 1-year high · trend down
Hedge-fund memo
Today
Trading higher by 1.45% amid a weak market, driven by strong revenue growth in the recent quarter.
This week
The stock has seen range-bound movement between 965 and 989.95 INR, indicating investor caution.
This month
The stock has slightly underperformed the broader market, with a gain of around 6% over the past month, compared to a 9% gain for NIFTY Pharma.
Bull thesis
Bear thesis
Narrative read
Neutral
Composite sentiment
Institutional
0.87 institutional buying interest, indicating a neutral institutional sentiment.
Retail
4.23 retail buying interest, suggesting a neutral retail sentiment.
News flow
No significant positive or negative news has impacted Jubilant Pharma stock price in the recent past.
Read
The neutral institutional and retail sentiment, combined with lack of significant news, suggests a relatively cautious view on the stock.
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 3 recent quarters (EPS actual vs. consensus).
8.1049 vs 8
1.31% surprise
5.01351 vs 6.9
-27.34% surprise
7.8452 vs 7.1
10.50% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| JUBLPHARMA | 152.31B | 38.28 | 5.96% | 9.72% | 18.70% |
| GLAND | 415.20B | 40.39 | 10.53% | 23.20% | 22.30% |
| ERIS | 190.57B | 29.30 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High debt levels pose a risk to Jubilant Pharma's balance sheet and interest expenses.
Mitigation: The company's ability to manage its debt and reduce its interest expenses will be crucial in mitigating this risk.
Intense competition in the generic space could erode market share.
Mitigation: Strategic partnerships and investments in research and development can help Jubilant Pharma maintain its competitive edge.
Business intelligence
Competitive moat
Jubilant Pharma's expertise in FDF manufacturing, research and development capabilities, and strategic partnerships create a competitive moat in the generic space.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Strong revenue growth and management guidance, potential M&A opportunities, and successful debt reduction efforts.
Thesis builder
Bull case
The company's strategic partnerships and operational efficiency will drive strong revenue growth, leading to a 20-25% 5-year CAGR.
Base case
Revenue growth will sustain, but at a moderate pace, driven by the steady execution of the company's business strategy.
Bear case
Intense competition, high debt levels, and potential regulatory challenges could limit Jubilant Pharma's revenue growth.
Time horizon
The next 6-12 months will be crucial in establishing whether the company's growth prospects are sustained.
Est. CAGR
10-15%
Entry (qual.)
Investors should consider entering at a 10-15% discount to the fair-value range to account for potential short-term volatility.
Exit (qual.)
Consider exiting when Jubilant Pharma's debt-to-equity ratio falls below 30% and the stock trades within the lower half of its 1-year range, providing a valuation buffer.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how JUBLPHARMA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain JUBLPHARMA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Investors should closely monitor Jubilant Pharma's debt reduction efforts and expansion plans to determine whether the stock's current valuation accurately reflects its growth prospects.
Annual income statement, oldest → newest. Live via Yahoo.
| 25.79% |
| 12.60% |
| AARTIDRUGS | 37.68B | 19.34 | 13.36% | 10.90% | 6.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹956.25
Resistance (day/52w high)
₹979.95
Volume
70,552
Trend
down
RSI (14)
52
MACD
bearish
MA cross
death
50-day MA
₹980.62
200-day MA
₹986.32
vs 200-DMA
-2.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 60%